Ipsen confirms US$1.31 bn agreement to buy Clementia Pharmaceuticals
Date: 2019-02-27   Author: Pankaj Singh  Category: #news

Ipsen confirms US$1.31 bn agreement to buy Clementia Pharmaceuticals

Ipsen pharma has recently announced that the company has entered into an agreement for acquiring Clementia Pharmaceuticals, with the boards of directors of both the firms allegedly approving this transaction. Apparently, completion of this deal is expected by the second quarter of 2019, subject to the fulfilment of all closing conditions.

The deal will supposedly expand the rare disease portfolio of Ipsen with palovarotene, Clementia’s late-stage drug candidate, which has rare pediatric disease as well as breakthrough therapy designations for an ultra-rare bone disorder and could be approved by 2020. 

On closing the transaction, Ipsen would be seemingly paying US$25 per share in cash up front, under the terms of the agreement, for an initial aggregate consideration of US$1.04 billion, along with deferred payments, which would bring the total consideration to US$1.31 billion. The initial cash consideration would represent a premium of 77 percent to the 30-day volume-weighted average stock price of Clementia.

A press release from Clementia reveals that this transaction would be fully financed through the lines of credit and existing cash of Ipsen, and would notably increase the level of net debt. This deal is anticipated to have a limited dilutive impact on the core operating margin of Ipsen for 2019 and 2020, provided the costs of ongoing clinical trials along with preparation for the commercial launch of palovarotene.

Chief Executive Officer of Ipsen, David Meek, mentioned that this acquisition of Clementia accelerates Ipsen’s ongoing transformation as the company is successfully executing on its external innovation strategy, for identifying and acquiring innovative medicines, in an attempt to serve patients with unmet medical needs.

Dr. Clarissa Desjardins, Clementia’s Chief Executive Officer, said in a statement that the global commercial capabilities and presence of Ipsen would expedite Clementia’s shared vision to bring palovarotene to patients across the globe as soon as possible. The company expects a smooth transition of its operations in the Ipsen organization which would continue the vision of Clementia to deliver palovarotene to patients globally.



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Gamma Cameras Market Expected to Witness High Growth over the Forecast Period 2020 - 2026
Author: Sachin Pashte

The Gamma Cameras Market report provides detailed competitive landscape of the global market. It includes company, market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the Global...


Copper Woven Wire Market Comprehensive Study with Key Trends, Major Drivers and Challenges 2020-2026
Author: Sachin Pashte

Market Study Report, LLC, has added a research study on ' Copper Woven Wire market' which extends an in-depth analysis of the potential factors fueling the revenue landscape of this industry. The study also comprises valuable insights abou...


Diagnostic Electrodes Market by Technology, Application & Geography Analysis & Forecast to 2026
Author: Sachin Pashte

The Global Diagnostic Electrodes Market Report includes a comprehensive analysis of the present industry status offering basic Diagnostic Electrodes overview and then goes into each and every detail.

The new research report on Diagnostic...